Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vorolanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vorolanib overview

Vorolanib is under development for the treatment of wet age-related macular degeneration and nonproliferative diabetic retinopathy (NPDR) diabetic macular edema and pathological myopia choroidal neovascularization (pmCNV). The drug candidate is a combination of a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib. It is administered through intravitreal route. The drug candidate acts by targeting VEGFR. The therapeutic candidate is developed based on Durasert technology and delivered using Medidur to provide sustained release. Medidur is a miniaturized, injectable, sustained-release drug delivery system. It was also under development for the treatment of dry age-related macular degeneration, retinal vein occlusion.

.

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals (EyePoint), formerly pSivida, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant to treat chronic non-infectious uvetis; and Dexycu for treatment of postoperative inflammation. EyePoint is headquartered in Watertown, Massachusetts, the US.

For a complete picture of Vorolanib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.